Just some  clarifications to Edward's e-mail posted under the heading "Reflections on the Scientific day.."

The FAQ referred to in the last lines of Edward's email stipulates that the software in which the AKI warning algorithm  operates must produce a test result (the AKI warning stage test result). This test result will be configured so that other clinical systems in primary and secondary can handle it in the same way that they would handle a serum creatinine result.
It becomes a universal "currency" for AKI warning which will be identical in each Trust within England.

The AKI Programe Board is not encouraging the development of the AKI warning algorithm within middleware.

The MHRA "licensing" referred to is not really licensing in the usual sense of the word. For this type of diagnostic device, the process involves self-certification rather than a specific approval of software. It is unlikely therefore that Sunquest will be able to claim MHRA approval or licensing for anything they might develop in ICE.